Floatz logo

Andes-1537 For

Advanced Unresectable Solid Tumors

Andes BiotechnologiesPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

1412 Active assets in the Advanced Unresectable Solid Tumors cohort.

Asset / SponsorPhaseRating
Nabiximols
Jazz Pharmaceuticals
Phase 3BBB
Inno-206
M.D. Anderson Cancer Center
Phase 2BB
Vitamin B6
M.D. Anderson Cancer Center
Phase 4BB
PROPOFOL
Hong Kong Children's Hospital
Phase 4BB
Rivoceranib
Jiangsu HengRui Medicine Co., Ltd.
Phase 4BB

View all 50 →

Same molecule, other indications

Andes-1537 For is also rated in:

gallbladder cancerDormant
CC
Indicative ·
46 / 100
View asset →
neoplasmDormant
CC
Indicative ·
44 / 100
View asset →
cervical cancerDormant
CC
Indicative ·
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →